Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY study, will be the focus of four …
Jetzt den vollständigen Artikel lesen